New Risk • Jun 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩281m revenue, or US$182k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (₩35.1b market cap, or US$22.7m). 공시 • Apr 17
Shaperon Inc. announced that it has received KRW 8.6 billion in funding On April 15, 2026, Shaperon Inc. has closed the transaction. 공시 • Apr 09
Shaperon Inc. announced that it expects to receive KRW 8.6 billion in funding Shaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000. 공시 • Mar 12
Shaperon Inc., Annual General Meeting, Mar 27, 2026 Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South Korea New Risk • Nov 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m). 공시 • Nov 14
Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in Boston Shaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds. 
